Aktienanalyse zu Evogene Ltd (EVGN)EVGNEvogene Ltd

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It operates in the Healthcare sector.

Evogene Ltd is currently not a strong buy due to its recent performance and financial metrics. The current price is $0.5496, which is significantly below the analyst target of $2.15, indicating potential upside. However, the company has a high RSI of 42.48, suggesting it is nearing oversold conditions, but it has also experienced a 51.36% decline year-to-date. The main risk is the net loss of $1.8 million in Q2 2026, which, while an improvement from previous quarters, still indicates ongoing financial challenges.

2 analysts cover EVGN: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 2.50.